Scarica l'app Stockscreener
1.26
6.67%
-0.09
Dopo l'orario di chiusura:
1.28
0.02
+1.59%
Precedente Chiudi:
$1.35
Aprire:
$1.39
Volume 24 ore:
1.92M
Relative Volume:
0.92
Capitalizzazione di mercato:
$145.32M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7636
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
-18.71%
1M Prestazione:
+4.13%
6M Prestazione:
-3.82%
1 anno Prestazione:
-48.15%
Intervallo 1D:
$1.23
$1.3995
Intervallo di 1 settimana:
$1.23
$1.565
Portata 52W:
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.26 | 155.70M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
What Fibonacci levels say about Fate Therapeutics Inc. reboundWeekly Trade Report & Capital Efficient Trading Techniques - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturnsVolume Spike & Technical Confirmation Trade Alerts - newser.com
Can trapped investors hope for a rebound in Fate Therapeutics Inc.Weekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Why Fate Therapeutics Inc. stock remains a top recommendation2025 Retail Activity & Real-Time Volume Triggers - newser.com
How to use a screener to detect Fate Therapeutics Inc. breakoutsMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Developing predictive dashboards with Fate Therapeutics Inc. dataWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Why Fate Therapeutics Inc. stock is a value investor pick2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Q3 Earnings Estimate for FATE Issued By HC Wainwright - MarketBeat
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Will Fate Therapeutics Inc. see short term momentumJuly 2025 Final Week & Free Community Consensus Stock Picks - newser.com
Multi factor analysis applied to Fate Therapeutics Inc.Earnings Growth Summary & Entry Point Strategy Guides - newser.com
Automated trading signals detected on Fate Therapeutics Inc.2025 Analyst Calls & AI Driven Stock Reports - newser.com
Will Fate Therapeutics Inc. stock recover faster than marketAnalyst Upgrade & Smart Investment Allocation Insights - newser.com
Is Fate Therapeutics Inc. stock undervalued vs historical averagesSell Signal & Free Safe Entry Trade Signal Reports - newser.com
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
How Fate Therapeutics Inc. stock benefits from global expansionEntry Point & Free Verified High Yield Trade Plans - newser.com
Fate Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
HC Wainwright & Co. Upgrades Fate Therapeutics (FATE) - Nasdaq
HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target - MarketScreener
Q3 Earnings Forecast for Fate Therapeutics Issued By Wedbush - MarketBeat
What drives Fate Therapeutics Inc stock priceVolume Weighted Average Price & Low Cost Trading Plans - earlytimes.in
Fate Therapeutics Reports Promising Phase 1 Trial Results - MSN
Is Fate Therapeutics Inc. stock resilient to inflation2025 Short Interest & Accurate Entry and Exit Point Alerts - Fundação Cultural do Pará
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):